Clinical Trial Update: Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing AVP-923 for levodopa-induced dyskinesia in Parkinson's disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia
• Parkinson Disease

Drugs mentioned

• AVP-923

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Dyskinesia, Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-04-29